Oral Administration of Polaprezinc Attenuates Fluorouracil‐induced Intestinal Mucositis in a Mouse Model

• DOI: 10.1111/bcpt.12841
• Publication Date: 2017-07-01T14:26:43Z
• Authors: Zhaoyang Liu; Wenbo Xie; Mingru Li; Nan Teng; Xiao Liang; Ziqiang Zhang; Zhaogang Yang; Xiaobing Wang
• Keywords: Mucositis

Abstract 5‐Fluorouracil (5‐FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents. However, it frequently causes intestinal mucosal injury and related side effects, such abdominal pain diarrhoea, which limit use 5‐FU in a clinic setting. Polaprezinc gradually become known protective agent for management gastric ulcer. This study aimed investigate prophylactic efficacy administered orally against mucositis induced by mice on condition that antitumour effect could not be compromised. We SPF‐grade ICR with 5‐FU, evaluated damage absence or presence Polaprezinc. examined score diarrhoea loss weight after treatment assessed integrity villus proliferation small intestine crypt cells haematoxylin eosin staining PCNA immunohistochemical detection. The was without xenograft model. result showed significantly reduced elevated body‐weight caused abolished histological abnormality cell hypoproliferation dose‐dependent manner, affecting colon tumour mice. conclude inhibit 5‐FU‐induced alleviate during chemotherapy, possible candidate prevention mucositis, through protecting mucosa improving quality life chemotherapy.